Search

Corvus Pharmaceuticals Inc

Gesloten

16.17 0.81

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

16

Max

16.44

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.4M

-14M

EPS

-0.15

Werknemers

37

EBITDA

312K

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+96.52% upside

Dividenden

By Acuity

Volgende Winsten

6 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-71M

1.3B

Vorige openingsprijs

15.36

Vorige sluitingsprijs

16.17

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jul 2026, 23:56 UTC

Sirius XM Holdings Inc shares are higher in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month trading range.

8 jul 2026, 23:56 UTC

MercadoLibre Inc. shares declined during after-market hours, reflecting broader market sentiment amid rising oil prices and inflationary pressures from Middle East tensions.

8 jul 2026, 23:56 UTC

Biogen Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing lower, with no specific news identified for the decline.

8 jul 2026, 23:52 UTC

UK House Price Balance Declines to -0.33%, Heightening Concerns Over Housing Market Stability Amid Economic Pressures

8 jul 2026, 23:52 UTC

Positive Shift in U.S. Home Sales Anticipated as June Data Shows 5.9% Year-over-Year Increase Ahead of July Release.

8 jul 2026, 23:52 UTC

Optimism Grows Ahead of July 9 Release for U.S. Existing Home Sales Amid Lower Mortgage Rates and Increased Listings

8 jul 2026, 23:52 UTC

Australia's Westpac Consumer Confidence Index shows a 3.5% drop, signaling ongoing economic concerns ahead of July 14 release amid inflationary pressures and market volatility.

8 jul 2026, 23:52 UTC

Australia's Westpac Consumer Confidence Index set for July 14, 2026 release amid cautious investor sentiment and global economic pressures.

8 jul 2026, 23:51 UTC

Gilead Sciences shares are lower in after-hours trading, reflecting a decline from earlier levels amid broader market weakness influenced by geopolitical tensions.

8 jul 2026, 23:51 UTC

News

Broadcom shares rise in after-market hours as analysts project $172 billion in revenue next year, driven by AI infrastructure spending.

8 jul 2026, 23:51 UTC

U.S. equity markets show mixed results amid rising oil prices and geopolitical tensions, with European markets declining sharply as inflation fears grow.

8 jul 2026, 23:51 UTC

Geopolitical tensions and rising oil prices drive mixed Asian equity markets, with European indices declining amid inflation concerns and revised global growth forecasts.

8 jul 2026, 23:51 UTC

Global equity markets decline amid rising oil prices and geopolitical tensions, with U.S. consumer credit unexpectedly falling.

8 jul 2026, 23:51 UTC

European equity markets drop as DAX 30 falls 2.5% amid escalating Middle East tensions, rising oil prices, and inflation concerns.

8 jul 2026, 23:51 UTC

Macro News
ETF Constituents
Correlated Moves

Materials Select Sector SPDR Fund declines in after-market hours amid geopolitical tensions affecting global oil markets and related asset sentiment.

8 jul 2026, 23:51 UTC

News
Social Media

Costco Wholesale reported net sales of $29.24 billion for June but shares declined in after-hours trading amid mixed investor sentiment and broader market trends.

8 jul 2026, 23:51 UTC

Correlated Moves

The NZD/HKD is higher today, reflecting a modest increase since Tuesday's close, despite declines in European markets, including the DAX 30 Index.

8 jul 2026, 23:51 UTC

Correlated Moves
Macro News

The New Zealand Dollar has strengthened against major currencies after the Reserve Bank raised its key interest rate to 2.50%.

8 jul 2026, 23:51 UTC

Macro News
ETF Constituents

iShares MSCI South Korea ETF declines in after-market hours amid KOSPI's significant drop and rising global economic concerns linked to Middle East tensions.

8 jul 2026, 23:51 UTC

Macro News
ETF Constituents

The iShares U.S. Aerospace & Defense ETF declined in after-market trading amid rising tensions from U.S. military strikes against Iranian targets, impacting key defense firms.

8 jul 2026, 23:51 UTC

Correlated Moves
Macro News

Bitcoin is trading lower amid rising geopolitical tensions following President Trump's ceasefire announcement with Iran. Earlier, it reached a session high before declining.

8 jul 2026, 23:46 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting routine trading activity with minimal fluctuations and positioning above the 20-day moving average.

8 jul 2026, 23:46 UTC

Fastenal Co shares are trading lower in after-market hours, marking the fifth consecutive day of declines amid broader market weakness linked to geopolitical tensions.

8 jul 2026, 23:46 UTC

Vertex Pharmaceuticals shares are higher in after-market trading, despite significant declines in European markets amid geopolitical tensions involving the U.S. and Iran.

8 jul 2026, 23:46 UTC

News
ETF Constituents
Macro News
Correlated Moves

The Financial Select Sector SPDR Fund is higher in after-market trading, supported by strong seasonal patterns and movements in major bank holdings.

8 jul 2026, 23:46 UTC

Western Digital shares are lower in after-market trading, amid broader market declines linked to geopolitical tensions affecting oil supply routes.

8 jul 2026, 23:41 UTC

News
Social Media
Correlated Moves

Advanced Micro Devices shares are declining in after-hours trading amid negative sentiment in semiconductor stocks, following the announcement of its upcoming earnings report.

8 jul 2026, 23:41 UTC

U.S. 30-Year Mortgage Rate Rises to 6.58%, Sparking Decline in Applications Amid Inflation and Economic Uncertainty

8 jul 2026, 23:41 UTC

Social Media
News

NVIDIA Corp shares declined in after-market trading amid concerns over AI spending and competition. Analysts note cautious investor sentiment contributing to the bearish outlook.

8 jul 2026, 23:41 UTC

News
Social Media
Correlated Moves

Micron Technology shares traded higher after notable options activity, with $7.2 million in orders for $815 7/17 Puts contributing to a total premium of over $21.5 million.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

96.52% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD  96.52%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat